Immuno Oncology and Technology Volume 21

Introduction: IOTECH, the sister journal to Annals of Oncology and ESMO Open, is the latest addition to the European Society for Medical Oncology’s prestigious journal portfolio. With a commitment to publishing high-quality original research articles, reviews, perspectives, technology explained papers, letters to the editor, and editorials, IOTECH serves as a distinguished forum for leading experts in the field of Immuno-Oncology.

Scope and Aims: Published quarterly under the guidance of Editor in Chief, Professor John Haanen, and an esteemed team of international Editors and Editorial Board members, IOTECH focuses on pre-clinical and clinical studies exploring natural and therapy-induced innate and adaptive immune responses against solid and hematological cancers. The journal aims to present cutting-edge research that advances our understanding of the immune system’s role in combating cancer.

Emphasis on Technological Advancements: IOTECH places a strong emphasis on technological developments in Immuno-Oncology. It seeks to showcase groundbreaking innovations that contribute to deciphering immune mechanisms and improving clinical outcomes. By highlighting the latest technological advances, the journal fosters a comprehensive understanding of Immuno-Oncology and its potential for revolutionizing cancer treatment.

Promoting Collaboration and Innovation: Through its commitment to publishing high-quality research and providing a platform for leaders in the field, IOTECH encourages collaboration and knowledge exchange among Immuno-Oncology researchers and clinicians. By promoting a multidisciplinary approach, the journal stimulates innovative thinking and fosters advancements in the field.

Expert Leadership: Led by a distinguished Editor in Chief and an international team of expert Editors and Editorial Board members, IOTECH ensures that the journal maintains its high standard of quality and relevance. The collective expertise of the editorial team ensures rigorous peer review and the selection of impactful research articles.

Conclusion: As a valuable addition to the European Society for Medical Oncology’s journal portfolio, IOTECH contributes significantly to the advancement of Immuno-Oncology research and technology. By publishing cutting-edge research, technological advancements, and expert perspectives, the journal strengthens the global Immuno-Oncology community and brings us closer to achieving improved clinical outcomes for cancer patients.

Volume 21: March 2024